MedTrace Logo

THCV Treatment for Smokers

NCT07636356 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-08-04

No results posted yet for this study

Summary

This study will randomize 32 non-treatment-seeking individuals who smoke cigarettes daily into a randomized, crossover, double-blind, placebo-controlled study testing the safety, tolerability, and initial efficacy of Δ9-tetrahydrocannabivarin (Δ9-THCV).

Conditions

  • Tobacco Use Disorder
  • Smoking Cessation

Interventions

DRUG

Δ9-Tetrahydrocannabivarin (oral gummy)

10mg Δ9-Tetrahydrocannabivarin oral gummy

DRUG

Matched Placebo (oral gummy)

Matched Placebo (oral gummy, 0mg Δ9-Tetrahydrocannabivarin)

Sponsors & Collaborators

Principal Investigators

  • Lara A Ray, PhD · University of California, Los Angeles

  • Erica N Grodin, PhD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2028-05-31
Completion
2028-05-31
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07636356 on ClinicalTrials.gov